Home Featured Page 300

Featured

Latest

The Psychedelic Practitioner Issue 2: Preparation

Evidence and Experience: Samuel Wilkinson on the State of (Es)ketamine Therapy and What Comes Next

The Psychedelic News Feed: December 1 – 7, 2025

The Psychedelic News Feed: November 24 – 30, 2025

Pα+ Psychedelic Bulletin #215: FDA’s Move to Single-Trial Approvals; Freedom to Heal Act Looks to Unlock Right to Try Psychedelics; Compass Clarifies Q1 Readout...

How Psychedelics Can Help Palliative and End-of-Life Care

Five Talking Points for People Skeptical of Psychedelic Therapy

The Future of MDMA Therapy: Promising Next Steps

How Psychedelics Can Treat PTSD

New Research Compares Placebo and Psychedelic Microdosing Benefits

Psychedelic Business News Spotlight: February 5, 2021

2 Massachusetts Cities Have Decriminalized Psychedelics in the Last Month

Interview With Dr. Hyder A. Khoja

Interview With Yaron Conforti, Novamind

5-MeO-DMT: Can ‘Toad Juice’ Cure Depression?

1...299300301...304 Page 300 of 304

The Psychedelic Practitioner Issue 2: Preparation

Evidence and Experience: Samuel Wilkinson on the State of (Es)ketamine Therapy...

The Psychedelic News Feed: December 1 – 7, 2025

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

The Psychedelic Practitioner Issue 2: Preparation

Evidence and Experience: Samuel Wilkinson on the State of (Es)ketamine Therapy and What Comes Next

The Psychedelic News Feed: December 1 – 7, 2025

The Psychedelic News Feed: November 24 – 30, 2025

Pα+ Psychedelic Bulletin #215: FDA’s Move to Single-Trial Approvals; Freedom to Heal Act Looks to Unlock Right to Try Psychedelics; Compass Clarifies Q1 Readout...

How Psychedelics Can Help Palliative and End-of-Life Care

Five Talking Points for People Skeptical of Psychedelic Therapy

The Future of MDMA Therapy: Promising Next Steps

How Psychedelics Can Treat PTSD

New Research Compares Placebo and Psychedelic Microdosing Benefits

Psychedelic Business News Spotlight: February 5, 2021

2 Massachusetts Cities Have Decriminalized Psychedelics in the Last Month

Interview With Dr. Hyder A. Khoja

Interview With Yaron Conforti, Novamind

5-MeO-DMT: Can ‘Toad Juice’ Cure Depression?

EDITOR PICKS

The Psychedelic Practitioner Issue 2: Preparation

Evidence and Experience: Samuel Wilkinson on the State of (Es)ketamine Therapy...

The Psychedelic News Feed: December 1 – 7, 2025

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY